94 related articles for article (PubMed ID: 17305414)
21. Voriconazole: review of a broad spectrum triazole antifungal agent.
Kofla G; Ruhnke M
Expert Opin Pharmacother; 2005 Jun; 6(7):1215-29. PubMed ID: 15957974
[TBL] [Abstract][Full Text] [Related]
22. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Spain.
Domínguez-Gil A; Martín I; García Vargas M; Del Castillo A; Díaz S; Sánchez C
Clin Drug Investig; 2007; 27(3):197-205. PubMed ID: 17305414
[TBL] [Abstract][Full Text] [Related]
23. Economic evaluation of voriconazole versus caspofungin for the treatment of invasive aspergillosis in Belgium.
Selleslag D; Vogelaers D; Marbaix S
Acta Clin Belg; 2009; 64(5):393-8. PubMed ID: 19999386
[TBL] [Abstract][Full Text] [Related]
24. Economic evaluation of targeted treatments of invasive aspergillosis in adult haematopoietic stem cell transplant recipients in the Netherlands: a modelling approach.
Ament AJ; Hübben MW; Verweij PE; de Groot R; Warris A; Donnelly JP; van 't Wout J; Severens JL
J Antimicrob Chemother; 2007 Aug; 60(2):385-93. PubMed ID: 17561501
[TBL] [Abstract][Full Text] [Related]
25. Economic evaluation of voriconazole versus conventional amphotericin B in the treatment of invasive aspergillosis in Germany.
Jansen JP; Kern WV; Cornely OA; Karthaus M; Ruhnke M; Ullmann AJ; Resch A
Value Health; 2006; 9(1):12-23. PubMed ID: 16441520
[TBL] [Abstract][Full Text] [Related]
26. [Efficacies and clinical roles of new antifungal agents].
Tokimatsu I; Kadota J
Nihon Ishinkin Gakkai Zasshi; 2006; 47(3):155-9. PubMed ID: 16940948
[TBL] [Abstract][Full Text] [Related]
27. Caspofungin versus liposomal amphotericin B for empirical therapy.
Danaher PJ
N Engl J Med; 2005 Jan; 352(4):410-4; author reply 410-4. PubMed ID: 15675092
[No Abstract] [Full Text] [Related]
28. Systemic antifungal therapy: Past, present and future.
Al-Mohsen I; Hughes WT
Ann Saudi Med; 1998; 18(1):28-38. PubMed ID: 17341911
[No Abstract] [Full Text] [Related]
29. Efficacy and safety of caspofungin for treatment of invasive aspergillosis in patients refractory to or intolerant of conventional antifungal therapy.
Maertens J; Raad I; Petrikkos G; Boogaerts M; Selleslag D; Petersen FB; Sable CA; Kartsonis NA; Ngai A; Taylor A; Patterson TF; Denning DW; Walsh TJ;
Clin Infect Dis; 2004 Dec; 39(11):1563-71. PubMed ID: 15578352
[TBL] [Abstract][Full Text] [Related]
30. [Invasive fungal infection in immunocompromised patients].
García-Ruiz JC; Amutio E; Pontón J
Rev Iberoam Micol; 2004 Jun; 21(2):55-62. PubMed ID: 15538828
[TBL] [Abstract][Full Text] [Related]
31. [Invasive aspergillosis: clinical manifestations and treatment].
Lumbreras C; Gavaldá J
Rev Iberoam Micol; 2003 Sep; 20(3):79-89. PubMed ID: 15456363
[TBL] [Abstract][Full Text] [Related]
32. Newer systemic antifungal agents : pharmacokinetics, safety and efficacy.
Boucher HW; Groll AH; Chiou CC; Walsh TJ
Drugs; 2004; 64(18):1997-2020. PubMed ID: 15341494
[TBL] [Abstract][Full Text] [Related]
33. [Clinical importance of azoles in antifungal therapy: treatment or prophylaxis with new azoles in hematology].
Vazquez Lopez L
Rev Esp Quimioter; 2004 Mar; 17(1):98-100. PubMed ID: 15201932
[No Abstract] [Full Text] [Related]
34. Voriconazole: A second-generation triazole.
Chandrasekar PH; Manavathu E
Drugs Today (Barc); 2001 Feb; 37(2):135-148. PubMed ID: 12783104
[TBL] [Abstract][Full Text] [Related]
35. Caspofungin.
Chandrasekar PH; Manavathu EK
Drugs Today (Barc); 2002 Dec; 38(12):829-46. PubMed ID: 12582472
[TBL] [Abstract][Full Text] [Related]
36. The safety of voriconazole.
Potoski BA; Brown J
Clin Infect Dis; 2002 Nov; 35(10):1273-5. PubMed ID: 12410490
[No Abstract] [Full Text] [Related]
37. Voriconazole versus amphotericin B for primary therapy of invasive aspergillosis.
Herbrecht R; Denning DW; Patterson TF; Bennett JE; Greene RE; Oestmann JW; Kern WV; Marr KA; Ribaud P; Lortholary O; Sylvester R; Rubin RH; Wingard JR; Stark P; Durand C; Caillot D; Thiel E; Chandrasekar PH; Hodges MR; Schlamm HT; Troke PF; de Pauw B;
N Engl J Med; 2002 Aug; 347(6):408-15. PubMed ID: 12167683
[TBL] [Abstract][Full Text] [Related]
38. Invasive aspergillosis in 2002: an update.
Kontoyiannis DP; Bodey GP
Eur J Clin Microbiol Infect Dis; 2002 Mar; 21(3):161-72. PubMed ID: 11957017
[TBL] [Abstract][Full Text] [Related]
39. Trends in mortality due to invasive mycotic diseases in the United States, 1980-1997.
McNeil MM; Nash SL; Hajjeh RA; Phelan MA; Conn LA; Plikaytis BD; Warnock DW
Clin Infect Dis; 2001 Sep; 33(5):641-7. PubMed ID: 11486286
[TBL] [Abstract][Full Text] [Related]
40. Aspergillosis case-fatality rate: systematic review of the literature.
Lin SJ; Schranz J; Teutsch SM
Clin Infect Dis; 2001 Feb; 32(3):358-66. PubMed ID: 11170942
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
